整理 | GLP1减重宝典内容团队礼来周四最新财报表示,其实验性 GLP-1 类口服减重药 orforglipron 在一项晚期临床试验中帮助患者平均减重 12.4%,显著优于安慰剂组的 0.9%,但仍低于竞争对手诺和诺德注射型减重药司美格鲁肽先前试验中的效果。这一结果引发投资者失望,礼来股价当日暴跌近 15%,为 25 年来最大单日跌幅,市值蒸发逾 1000 亿美元,成为当天拖累标普 500 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.